| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 27, 2021 | NBIX Neurocrine Biosciences Inc | Lloyd-Smith Malcolm49 | Chief Regulatory Officer | Sell | 16,709 | $93.80 | $1,567,335.95 | -51.4% | +9.0% | +1.5% | |
| Jul 26, 2021 | AMPH Amphastar Pharmaceuticals, Inc. | Zhou Rong59 | EVP, Production Center | Sell | 6,000 | $20.87 | $125,220.00 | -6.5% | -7.7% | +79.4% | |
| Jul 22, 2021 | YCBD Cbdmd, Inc. | Wiesehan John J III | Chief Revenue Officer | Buy | 161,550 | $0.00 | - | New | -21.4% | -82.8% | |
| Jul 22, 2021 | ZTS Zoetis Inc. | Lagano Roxanne70 | Executive Vice President | Sell | 22,450 | $199.18 | $4,471,609.70 | -24.1% | +2.9% | -10.6% | |
| Jul 21, 2021 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 86,111 | $237.00 | $20,408,307.00 | - | +2.4% | +39.7% | |
| Jul 21, 2021 | HROW Harrow, Inc. | Opaleye Management Inc.60 | - | Buy | 20,000 | $7.31 | $146,289.84 | +0.2% | +33.2% | -4.6% | |
| Jul 20, 2021 | AMPH Amphastar Pharmaceuticals, Inc. | Zhou Rong59 | EVP, Production Center | Sell | 5,187 | $20.57 | $106,696.59 | -5.7% | -5.6% | +76.6% | |
| Jul 20, 2021 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 15,610 | $237.06 | $3,700,428.55 | - | +2.0% | +39.0% | |
| Jul 19, 2021 | ORGO Organogenesis Holdings Inc. | Gillheeney Gary S.73 | President And CEO | Sell | 300,000 | $14.35 | $4,306,342.78 | -41.4% | -22.0% | -62.1% | |
| Jul 16, 2021 | TLRY Tilray Brands, Inc. | Kennedy Brendan87 | Director | Sell | 600,000 | $14.35 | $8,612,267.76 | -2.2% | -25.3% | -76.3% | |
| Jul 15, 2021 | AMPH Amphastar Pharmaceuticals, Inc. | Liawatidewi Yakob47 | EVP Corp Admin Center | Sell | 31,524 | $20.01 | $630,688.06 | -36.8% | -4.0% | +84.8% | |
| Jul 15, 2021 | BCRX Biocryst Pharmaceuticals Inc | Abercrombie George B68 | Director | Sell | 5,000 | $15.69 | $78,450.00 | -62.5% | -5.1% | -26.3% | |
| Jul 14, 2021 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 10,780 | $237.02 | $2,555,118.72 | - | -1.2% | +40.3% | |
| Jul 14, 2021 | BUDZ Weed, Inc. | Breen Nicole M | Secretary/ Treasurer | Sell | 23,000 | $0.37 | $8,556.00 | -0.1% | - | - | |
| Jul 12, 2021 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 3,238 | $237.09 | $767,694.18 | - | -0.7% | +39.0% | |
| Jul 9, 2021 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 109,261 | $237.39 | $25,937,090.76 | - | -0.4% | +42.6% | |
| Jul 7, 2021 | AMPH Amphastar Pharmaceuticals, Inc. | Peters William J52 | CFO, EVP &Treasurer | Sell | 10,000 | $20.37 | $203,739.00 | -8.2% | -7.4% | +78.9% | |
| Jul 7, 2021 | TAK Takeda Pharmaceutical Co Ltd | Takeda Pharmaceutical Co Ltd70 | 10% Owner | Sell | 2,609 | $35.05 | $91,445.45 | -0.3% | -1.2% | -9.3% | |
| Jul 6, 2021 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 210,000 | $235.09 | $49,369,047.00 | -0.2% | -4.2% | +42.2% | |
| Jul 2, 2021 | GSK Gsk Plc | Glaxosmithkline Plc | 10% Owner | Buy | 275,000 | $18.00 | $4,950,000.00 | +37.5% | -4.3% | +11.8% | |
| Jul 2, 2021 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 202,102 | $232.94 | $47,077,748.98 | - | -0.9% | +40.7% | |
| Jul 2, 2021 | PCRX Pacira Biosciences, Inc. | Reinhardt Max79 | President, Rest Of World | Sell | 421 | $59.76 | $25,158.96 | -2.3% | -5.5% | -2.4% | |
| Jul 2, 2021 | TAK Takeda Pharmaceutical Co Ltd | Takeda Pharmaceutical Co Ltd70 | 10% Owner | Sell | 8,326 | $35.16 | $292,727.16 | -0.5% | -0.8% | -13.0% | |
| Jul 1, 2021 | ALKS Alkermes Plc. | Anstice David W | Director | Sell | 20,000 | $24.58 | $491,504.00 | -21.5% | +24.1% | +22.6% | |
| Jul 1, 2021 | ZTS Zoetis Inc. | Trawicki Roman48 | Executive Vice President | Sell | 4,492 | $187.00 | $840,004.00 | -78.8% | +3.1% | -7.4% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.